North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
作者信息
Bergsland Emily K, Halperin Daniel M, Dillon Joseph S, Dasari N Arvind, Kunz Pamela L, Soares Heloisa P, Pryma Daniel, Bodei Lisa, Hope Thomas, Soulen Michael C, Mailman Josh, Howe James R
机构信息
From the Department of Medicine, University of California San Francisco, San Francisco, CA.
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Pancreas. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561.
Abstract
摘要
相似文献
1
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.北美神经内分泌肿瘤协会针对新冠疫情期间神经内分泌肿瘤患者医疗服务提供者的指南
Pancreas. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561.
2
Redistributing working schedules using the infective principle in the response to COVID-19.在应对2019冠状病毒病时运用感染原理重新分配工作时间表。
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1123-1124. doi: 10.1017/ice.2020.155. Epub 2020 Apr 21.
3
The Adverse Impact of COVID-19 on Health Care Providers: Time to Start Measuring.新冠疫情对医护人员的不利影响：是时候开始进行评估了。
Anesth Analg. 2020 Oct;131(4):e187-e189. doi: 10.1213/ANE.0000000000005088.
4
Protection of nephrology health professionals during the COVID-19 pandemic.2019冠状病毒病大流行期间对肾脏病学医护人员的保护。
Nefrologia (Engl Ed). 2020 Jul-Aug;40(4):395-402. doi: 10.1016/j.nefro.2020.06.001. Epub 2020 Jul 1.
5
[Management guidelines for vulnerable workers and persons and SARS-CoV-2 in Catalonian businesses].[加泰罗尼亚企业中弱势劳动者及人员与新型冠状病毒肺炎的管理指南]
Arch Prev Riesgos Labor. 2020 Apr 15;23(2):234-252. doi: 10.12961/aprl.2020.23.02.8.
6
Nuclear cardiology in the COVID-19 pandemic era.新冠疫情时代的核医学心脏病学
Arch Cardiovasc Dis. 2020 Jun-Jul;113(6-7):374-377. doi: 10.1016/j.acvd.2020.05.003. Epub 2020 Jun 18.
7
[Healthcare workers from COVID-19 matters too much].[来自新冠疫情的医护人员也至关重要] 。 但原英文表述不太准确规范，正常可能是“Healthcare workers in the COVID-19 context matter too much” 。
J Healthc Qual Res. 2020 Sep-Oct;35(5):331-332. doi: 10.1016/j.jhqr.2020.04.002. Epub 2020 May 15.
8
Pancreaticobiliary Endoscopy in the COVID-19 Pandemic Era.新冠疫情时代的胰胆内镜检查
Pancreas. 2020 Jul;49(6):729-732. doi: 10.1097/MPA.0000000000001580.
9
How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.新冠病毒如何为结核病研究提供指导：确保接触传染病的研究人员的安全。
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):978-980. doi: 10.5588/ijtld.20.0454.
10
The largest epicenter of the coronavirus outbreak in Vietnam.越南新冠病毒疫情最大的疫情中心。
Infect Control Hosp Epidemiol. 2020 Aug;41(8):984-985. doi: 10.1017/ice.2020.128. Epub 2020 Apr 13.
引用本文的文献
1
Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center.COVID-19 大流行期间的胰腺神经内分泌肿瘤手术：来自高容量中心的回顾性队列研究。
Updates Surg. 2024 Sep;76(5):1827-1832. doi: 10.1007/s13304-024-01942-z. Epub 2024 Jul 21.
2
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.2019 年冠状病毒病患者的神经内分泌肿瘤：INTENSIVE 研究的初步结果。
Eur J Cancer. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30.
3
Impact of the COVID-19 pandemic on neuroendocrine tumour services in England.新冠疫情对英格兰神经内分泌肿瘤服务的影响。
Endocrine. 2021 Jan;71(1):14-19. doi: 10.1007/s12020-020-02564-2. Epub 2021 Jan 5.
4
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.《COVID-19 时代胃肠胰和胸部（类癌）神经内分泌肿瘤患者管理的实用建议》
Eur J Cancer. 2021 Feb;144:200-214. doi: 10.1016/j.ejca.2020.11.037. Epub 2020 Dec 25.
5
Professional Assessment of the Impact of COVID-19 on Handling NET Patients.新型冠状病毒肺炎（COVID-19）对神经内分泌肿瘤（NET）患者治疗影响的专业评估
J Clin Med. 2020 Nov 11;9(11):3633. doi: 10.3390/jcm9113633.
6
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间癌症护理临床实践指南及治疗建议综述
Cancers (Basel). 2020 Aug 29;12(9):2452. doi: 10.3390/cancers12092452.
本文引用的文献
1
Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.《[Lu-DOTA,Tyr]octreotate 治疗胃肠胰和支气管神经内分泌肿瘤患者的长期疗效、生存和安全性》。
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.
2
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
3
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.基于¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗在转移性胃肠胰神经内分泌肿瘤中的应用：一项与原发肿瘤部位、肿瘤增殖指数及双示踪剂成像特征相关的多参数反应评估
Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547.
4
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.依维莫司治疗晚期肺或胃肠道无功能性神经内分泌肿瘤（RADIANT-4）：一项随机、安慰剂对照的3期研究。
Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
5
Everolimus for advanced pancreatic neuroendocrine tumors.依维莫司治疗晚期胰腺神经内分泌肿瘤。
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
Zotero 插件